Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCREVUS vs GAZYVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells. It binds to the CD20 antigen expressed on pre-B cells, mature B cells, and memory B cells, but not on plasma cells or hematopoietic stem cells. Binding induces antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.
Obinutuzumab is a type II anti-CD20 monoclonal antibody that binds to the CD20 antigen on B cells, inducing direct cell death, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis.
Relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Primary progressive multiple sclerosis (PPMS)
Chronic lymphocytic leukemia (CLL) in combination with chlorambucil,Follicular lymphoma (FL) in combination with bendamustine followed by obinutuzumab monotherapy for patients with relapsed or refractory FL,Previously untreated follicular lymphoma in combination with chemotherapy
300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion; then 600 mg intravenous infusion every 6 months.
100 mg intravenously on day 1, 8, 15 of cycle 1, then 100 mg on day 1 of subsequent 28-day cycles for 6 cycles total.
Terminal elimination half-life is approximately 26 days (range: 18–39 days) for the 600 mg intravenous dose. This supports every-6-month dosing for sustained B-cell depletion.
The terminal elimination half-life is approximately 28 days (range 14-42 days) following the last dose, supporting a 6-month dosing interval for maintenance therapy.
Ocrelizumab is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes are involved, and it does not rely on hepatic or renal pathways for clearance.
Obinutuzumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous immunoglobulins; not metabolized by CYP450 enzymes.
Ocrelizumab is a humanized monoclonal antibody that is catabolized by general protein degradation pathways; it is not excreted renally or hepatically. Less than 1% is eliminated unchanged in urine. Biliary/fecal excretion is negligible as intact Ig G.
Obinutuzumab is eliminated primarily through intracellular catabolism, with no significant renal or biliary excretion. <1% of the dose is excreted unchanged in urine.
Ocrelizumab is an Ig G1 monoclonal antibody; it does not bind to plasma proteins. Estimated protein binding is negligible (< 1%).
Obinutuzumab binds specifically to CD20 antigen on B-cells; plasma protein binding is negligible (<1%) as it is a monoclonal antibody.
Volume of distribution is approximately 2.78 L (range: 1.89–4.23 L), which corresponds to about 0.04 L/kg for a 70 kg adult. This low Vd indicates distribution primarily in the vascular and interstitial spaces.
The volume of distribution is approximately 3.8 L (0.05 L/kg for a 70 kg adult), reflecting limited extravascular distribution primarily to lymphoid tissues.
Ocrelizumab is only administered intravenously; bioavailability is 100% by the IV route. Subcutaneous or oral routes are not approved; bioavailability via these routes is unknown.
Obinutuzumab is only administered intravenously; oral bioavailability is 0%. Subcutaneous formulations are not available.
No dose adjustment required for mild to moderate renal impairment; not studied in severe renal impairment (Cr Cl <15 m L/min).
No dose adjustment required for mild to moderate renal impairment (Cr Cl >=30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C).
Safety and efficacy in pediatric patients (<18 years) have not been established; no dosage recommendation.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment required based on age; consider comorbidities and concomitant medications. Clinical studies included patients up to age 65, limited data in >65 years.
No specific dose adjustment required; monitor for infusion-related reactions and hematologic toxicities more frequently.
None
Hepatitis B virus reactivation, including fulminant hepatitis, hepatic failure, and death; Progressive multifocal leukoencephalopathy (PML) resulting in death.
Infusion reactions: May require premedication; monitor during infusion,Infections: Increased risk, including herpes zoster and respiratory tract infections; screen for hepatitis B virus before initiation,Progressive multifocal leukoencephalopathy (PML): Rare but serious; discontinue if suspected,Immunoglobulin levels: Monitor; low Ig G associated with increased infection risk,Malignancies: Possible increased risk, particularly breast cancer,Fetal harm: Avoid in pregnancy; women of childbearing potential should use contraception
Infusion reactions (including severe and life-threatening reactions),Tumor lysis syndrome,Neutropenia and thrombocytopenia,Infections (including severe and opportunistic infections),Hepatitis B reactivation,Progressive multifocal leukoencephalopathy (PML),Immunization with live viral vaccines
Active hepatitis B virus infection,History of life-threatening infusion reaction to ocrelizumab,Severe, active infections (e.g., tuberculosis, sepsis)
Known hypersensitivity to obinutuzumab or any excipient,Active hepatitis B infection
No food interactions have been reported with ocrelizumab. The medication is administered intravenously, and there are no dietary restrictions required.
No known food interactions. Grapefruit and other CYP3A4 inhibitors are not expected to affect obinutuzumab as it is a monoclonal antibody cleared by non-renal, non-hepatic mechanisms.
Ocrevus (ocrelizumab) is a humanized monoclonal antibody that depletes CD20-positive B cells. Ig G antibodies cross the placenta, especially in the third trimester. There are no adequate and well-controlled studies in pregnant women. In animal studies, ocrelizumab was not teratogenic but caused B-cell depletion in offspring. Use is not recommended unless the benefit outweighs the risk. Based on limited human data, there is no known structural teratogenicity; however, the potential for B-cell depletion and immunosuppression in the fetus, particularly if administered during the second and third trimesters, exists.
First trimester: limited human data, but based on mechanism (anti-CD20 monoclonal antibody), potential B-cell depletion in fetus. Second/third trimesters: Ig G crosses placenta; fetal B-cell depletion and cytopenias possible. Avoid unless benefit outweighs risk.
It is not known whether ocrelizumab is excreted in human milk. Human Ig G is present in breast milk, and limited data suggest that monoclonal antibodies are transferred in small amounts. The M/P ratio is not established for ocrelizumab. Caution should be exercised; the decision to breastfeed should consider the mother's need for therapy, the potential for drug excretion, and the infant's immune status.
No data on presence in human milk; however, Ig G antibodies are excreted in breast milk. M/P ratio unknown. Discontinue breastfeeding or avoid drug due to potential for B-cell depletion in infant.
No specific dose adjustments are recommended for pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume) may affect drug levels, but no dose adjustment guidelines are established. The manufacturer advises avoiding use in pregnancy unless clearly necessary, and no dose modification is specified.
No specific dose adjustments recommended; pharmacokinetics may be altered due to increased volume of distribution and clearance. Use standard dosing if clinically indicated, with careful monitoring of efficacy and toxicity.
Ocrevus (ocrelizumab) is a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells. It is administered as an intravenous infusion. Premedication with methylprednisolone, an antihistamine, and an antipyretic is required to reduce infusion-related reactions. Screen for hepatitis B virus (HBV) infection before initiating therapy; do not use in patients with active HBV. Monitor for infections, especially upper respiratory tract infections, herpes, and urinary tract infections. Live and live-attenuated vaccines are contraindicated during treatment and until B-cell repletion. Administer all required vaccines at least 4-6 weeks before starting therapy. No dose adjustment needed for renal or hepatic impairment.
Administer premedication (acetaminophen, antihistamine, corticosteroid) for infusion reactions. Monitor for tumor lysis syndrome (TLS) and provide prophylaxis (hydration, uric acid reducers) in high-risk patients. Do not administer live vaccines during treatment. Screen for hepatitis B virus (HBV) infection before initiation. Use in CLL patients with del(17p) or TP53 mutation is an NCCN category 1 recommendation.
Ocrevus is given as an intravenous infusion every 6 months.,You will receive premedication before each infusion to reduce the risk of infusion reactions.,Report any symptoms of infection promptly, including fever, cough, or painful urination.,Avoid receiving live vaccines while on Ocrevus and for a period after treatment.,Tell your doctor if you have a history of hepatitis B infection.,You may be at increased risk for certain cancers, including breast cancer; follow recommended screening.,Inform all healthcare providers that you are taking Ocrevus.
You will receive premedication before each infusion to reduce infusion reactions.,Report any fever, chills, rash, or difficulty breathing during or after infusion immediately.,Do not receive live vaccines during treatment and for at least 6 months after last dose.,Your doctor will monitor for signs of tumor lysis syndrome (e.g., nausea, vomiting, muscle cramps, seizures).,You may be at increased risk of infections; report any signs of infection (fever, cough, sore throat).,This drug can lower blood counts; you may need regular blood tests.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCREVUS vs GAZYVA, answered by our medical review team.
OCREVUS is a CD20-directed monoclonal antibody that works by Ocrelizumab is a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells. It binds to the CD20 antigen expressed on pre-B cells, mature B cells, and memory B cells, but not on plasma cells or hematopoietic stem cells. Binding induces antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.. GAZYVA is a CD20-directed Monoclonal Antibody that works by Obinutuzumab is a type II anti-CD20 monoclonal antibody that binds to the CD20 antigen on B cells, inducing direct cell death, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCREVUS and GAZYVA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCREVUS is: 300 mg intravenous infusion followed 2 weeks later by a second 300 mg intravenous infusion; then 600 mg intravenous infusion every 6 months.. The standard adult dose of GAZYVA is: 100 mg intravenously on day 1, 8, 15 of cycle 1, then 100 mg on day 1 of subsequent 28-day cycles for 6 cycles total.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCREVUS and GAZYVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCREVUS is classified as Category C. Ocrevus (ocrelizumab) is a humanized monoclonal antibody that depletes CD20-positive B cells. IgG antibodies cross the placenta, especially in the third trimester. There are no ade. GAZYVA is classified as Category C. First trimester: limited human data, but based on mechanism (anti-CD20 monoclonal antibody), potential B-cell depletion in fetus. Second/third trimesters: IgG crosses placenta; fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.